Evidence of CCR5 as a therapeutic target was based on the finding that individuals with a high-risk for infection continued to live free of HIV-1 because of a CCR5 32bp-deletion (CCR5-Δ32) in homozygotes8,9. Here, CCR5 is linked to infection.